Incretin Atlas › Trials › SYNCHRONIZE-CVOT
SYNCHRONIZE-CVOT
Survodutide · Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD), obesity
Design
- Molecule(s)
- Survodutide
- Population
- Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD), obesity
- Official title
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
- Sponsor
- Boehringer Ingelheim
- Phase
- 3
- Registry status
- completed · 2023-11 → 2026-06
- Participants
- 5530
- Duration
- 72 weeks
- Registry
- NCT06077864
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| survodutide 3.6 mg | obesity | 72 | — | — | −9.3 % vs −2.4 % Δ −6.9 pp | — | 28.2 vs 11.1 | 44.0 vs 41.0 | 48.0 vs 12.1 | 31.7 vs 4.8 | 22.5 vs 23.9 | −4.3 vs −1.7 | verified |
| survodutide 6.0 mg | obesity | 72 | — | — | −9.7 % vs −2.4 % Δ −7.3 pp | — | 29.1 vs 11.1 | 43.4 vs 41.0 | 49.0 vs 12.1 | 34.0 vs 4.8 | 20.8 vs 23.9 | −4.9 vs −1.7 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- survodutide 3.6 mg: CV outcomes trial in a mixed population: obesity at increased CV risk, 52.7 % with type 2 diabetes, 52.8 % coronary artery disease, 10.9 % heart failure. Weight and SBP at week 72 (treatment-regimen); safety over the treatment period (median exposure 19 months). Not used in Map 6 (indirect comparisons combine only trials of the same population).
- survodutide 6.0 mg: CV outcomes trial in a mixed population: obesity at increased CV risk, 52.7 % with type 2 diabetes, 52.8 % coronary artery disease, 10.9 % heart failure. Weight and SBP at week 72 (treatment-regimen); safety over the treatment period (median exposure 19 months). Not used in Map 6 (indirect comparisons combine only trials of the same population).
Verbatim quotes from the source (14)
- survodutide 3.6 mg · weight_tp · Table 3
Mean change in bodyweight −9·3% −9·7% −2·4%
- survodutide 3.6 mg · ae_dc · Table 4
Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
- survodutide 3.6 mg · disc_any · Results, paragraph 2 (also Figure 1)
807 (44·0%) participants in
- survodutide 3.6 mg · nausea · Table 4
Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
- survodutide 3.6 mg · vomiting · Table 4
Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
- survodutide 3.6 mg · sae · Table 4
Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
- survodutide 3.6 mg · sbp · Table 2
Survodutide 3·6 mg: absolute change 1836 −4·29 1836 −1·72
- survodutide 6.0 mg · weight_tp · Table 3
Mean change in bodyweight −9·3% −9·7% −2·4%
- survodutide 6.0 mg · ae_dc · Table 4
Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
- survodutide 6.0 mg · disc_any · Results, paragraph 2 (also Figure 1)
796 (43·4%) in the
- survodutide 6.0 mg · nausea · Table 4
Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
- survodutide 6.0 mg · vomiting · Table 4
Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
- survodutide 6.0 mg · sae · Table 4
Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
- survodutide 6.0 mg · sbp · Table 2
Survodutide 6·0 mg: absolute change 1835 −4·89 1836 −1·72
Cardiovascular and kidney outcomes
SYNCHRONIZE-CVOT survodutide 3.6 or 6.0 mg once weekly (pooled) vs placebo · Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD) · n = 5530 · 2026 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| Expanded MACE primary Primary endpoint: five-point MACE = time to first CV death, non-fatal stroke, non-fatal MI, ischaemia-related coronary revascularisation, or heart failure event (HHF, ED visit, urgent care visit or urgent outpatient HF visit); non-inferiority margin 1.65 | 0.89 | 0.67–1.18 | 136 vs 76 | verified |
| 3-point MACE Key secondary: three-point MACE = CV death, non-fatal stroke, non-fatal MI (non-inferiority vs placebo) | 0.84 | 0.60–1.18 | 88 vs 52 | verified |
| 4-point MACE Four-point MACE as defined by the trial = CV death, non-fatal stroke, non-fatal MI, or ischaemia-related coronary revascularisation | 0.93 | 0.67–1.29 | 103 vs 55 | verified |
| Cardiovascular death Adjudicated death from cardiovascular causes (component of primary endpoint) | 1.05 | 0.49–2.23 | 21 vs 10 | verified |
| All-cause death All-cause mortality | 1.20 | 0.73–1.97 | 53 vs 22 | verified |
| Myocardial infarction Adjudicated non-fatal myocardial infarction — non-fatal events only | 0.99 | 0.60–1.64 | 46 vs 23 | verified |
| Stroke Adjudicated non-fatal stroke — non-fatal events only | 0.72 | 0.41–1.27 | 29 vs 20 | verified |
| Heart failure event Heart failure event, broader than hospitalisation alone: hospitalisation, emergency department visit, urgent care visit or urgent outpatient heart failure visit (adjudicated). CV death or hospitalisation for HF: HR 0.86 (0.55–1.35). | 0.76 | 0.46–1.25 | 40 vs 26 | verified |
| CV death or worsening HF First occurrence of adjudicated CV death or adjudicated heart failure event (HF event incl. HHF, ED/urgent visits) | 0.80 | 0.52–1.22 | 56 vs 35 | verified |
| Coronary revascularisation Adjudicated ischaemia-related coronary revascularisation | 2.49 | 0.85–7.30 | 20 vs 4 | verified |
| New-onset diabetes Onset of (protocol-defined) type 2 diabetes in participants without type 2 diabetes at baseline | 0.28 | 0.16–0.50 | 18 vs 32 | verified |
Verbatim quotes (11)
- Expanded MACE · Table 2, primary composite endpoint row, p 8
Pooled survodutide: primary composite 136 (3·7%) 2·15 76 (4·1%) 2·42 0·89 ·· ·· <0·0001 endpoint (five-point MACE)* (non- (0·67 to 1·18)†
- 3-point MACE · Table 2, key secondary endpoints, p 8
Pooled survodutide: three-point 88 (2·4%) 1·38 52 (2·8%) 1·64 0·84 ·· ·· <0·0001 MACE (non-inferiority vs placebo)‡ (0·60 to 1·18)
- 4-point MACE · Table 2 (continued), other secondary endpoints, p 9
First occurrence of any adjudicated 103 (2·8%) 1·62 55 (3·0%) 1·74 0·93 ·· ·· NA component of four-point MACE§ (0·67 to 1·29)
- Cardiovascular death · Table 2, primary endpoint components, p 8
Death from cardiovascular causes 21 (0·6%) 0·32 10 (0·5%) 0·30 1·05 ·· ·· NA (0·49 to 2·23)
- All-cause death · Table 2 (continued), other secondary endpoints, p 9
All-cause mortality 53 (1·4%) 0·80 22 (1·2%) 0·67 1·20 ·· ·· NA (0·73 to 1·97)
- Myocardial infarction · Table 2, primary endpoint components, p 8
Non-fatal myocardial infarction 46 (1·3%) 0·72 23 (1·3%) 0·72 0·99 ·· ·· NA (0·60 to 1·64)
- Stroke · Table 2, primary endpoint components, p 8
Non-fatal stroke 29 (0·8%) 0·45 20 (1·1%) 0·63 0·72 ·· ·· NA (0·41 to 1·27)
- Heart failure event · Table 2, primary endpoint components, p 8
Heart failure event† 40 (1·1%) 0·63 26 (1·4%) 0·82 0·76 ·· ·· NA (0·46 to 1·25)
- CV death or worsening HF · Table 2 (continued), other secondary endpoints, p 9
First occurrence of adjudicated death 56 (1·5%) 0·88 35 (1·9%) 1·10 0·80 ·· ·· NA from cardiovascular causes or (0·52 to 1·22)
- Coronary revascularisation · Table 2, primary endpoint components, p 8
Ischaemia-related coronary 20 (0·5%) 0·31 4 (0·2%) 0·12 2·49 ·· ·· NA revascularisation (0·85 to 7·30)
- New-onset diabetes · Table 2 (continued), other secondary endpoints, p 9
Onset of type 2 diabetes in 18 (1·1%) 0·60 32 (3·6%) 2·10 0·28 ·· ·· NA participants without type 2 diabetes (0·16 to 0·50)
Primary sources
- Bozkurt B, le Roux CW, Wharton S, Butt JH, Startseva E, Sumin M, et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Nov 9. doi:10.1016/S0140-6736(26)02140-9. Available from: https://doi.org/10.1016/S0140-6736(26)02140-9
- Boehringer Ingelheim. A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD. ClinicalTrials.gov identifier NCT06077864. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06077864
How to cite this page
Medical Adviser's Group. Incretin Atlas: SYNCHRONIZE-CVOT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-cvot/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.